Pfiz­er pre­dicts a $15B avalanche of cash from its Covid-19 vac­cine in 2021 as the R&D team claims a big spike in the tri­al suc­cess rate

If any­one wants a les­son in the val­ue of be­ing first-in-class and best-in-class in the drug busi­ness, pick up a copy of Pfiz­er’s quar­ter­ly re­port to­day.

The phar­ma gi­ant, long con­sid­ered a lum­ber­ing be­he­moth in R&D, picked up a rad­i­cal new mR­NA vac­cine from BioN­Tech for Covid-19 and just spiked the ball in the com­mer­cial end zone — all in­side of a year. And they’ve al­ready lined up enough con­tracts to back a pledge that this vac­cine will bring in a to­tal of $15 bil­lion in 2021 alone — half of which they can keep.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN